Electronic health record data from 17 US health systems between 1/1/2021-12/31/2024 were analyzed to determine the prevalence of Lp(a) testing among adults with ASCVD and changes in LDL-C management in those who are identified to have elevated Lp(a) levels.
N. Shah, P. Shrader, N. Freeman et al.· European Heart Journal· 0 citations
PURPOSE OF REVIEW
Oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a new generation of lipid-lowering therapies that combine the potency of injectable PCSK9 inhibitors with the convenience of oral administration. This review examines the mechanisms, trial evidence, and implementation cons...
Danh Q. Nguyen, N. Pagidipati, A. Navar· Current Opinion in Lipidolog...· 0 citations
BACKGROUND
Although the effectiveness of Lp(a) (lipoprotein[a])-lowering therapies remains under study, lipid guidelines now recommend Lp(a) testing in all adults to identify individuals who need more aggressive risk factor modification. Therefore, we evaluate contemporary patterns of Lp(a) testing and the impact of te...
Nishant P. Shah, P. Shrader, Nikki L. B. Freeman et al.· Circulation. Population heal...· 0 citations
In ASCVD patients, LDL-C levels plateau well above guideline targets following an initial decline, and proactive, system-level monitoring and timely intervention are urgently needed to reduce cumulative above-goal LDL-C exposure.
S. Shoji, P. Shrader, Nikki L. B. Freeman et al.· JACC: Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.